Action of tacrolimus on Wistar rat kidneys implanted with Walker 256 carcinosarcoma

Acta Cirurgica Brasileira

Volumn 25, Issue 1, 2010, Pages 98-104

  Inácio, Cristiano Machado ^a   Dietz, Ulrich Andréas ^a   Malafaia, Osvaldo ^a,b   Ribas Filho, Jurandir Marcondes ^a   Nassif, Paulo Afonso Nunes ^a   Czeczko, Nicolau Gregori ^a   Marcondes, Carmen Australia Paredes ^a  

^a University Evangelic Hospital   (Brazil)

^b Postgraduation Program   (Brazil)

Author keywords

Carcinoma 256, walker; Rats; Tacrolimus; Tacrolimus binding proteins

Indexed keywords

CREATININE; EOSIN; HEMATOXYLIN; SODIUM CHLORIDE; TACROLIMUS;

ANESTHESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOLOGICAL MODEL; BLEEDING; BLOOD SAMPLING; CANCER GROWTH; CANCER INVASION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG ACTIVITY; EUTHANASIA; FEEDING; KIDNEY CARCINOMA; MALE; NEPHROTOXICITY; NONHUMAN; RAT; UREA NITROGEN BLOOD LEVEL; WALKER CARCINOMA;

EID: 76149135700     PISSN: 01028650     EISSN: 16782674     Source Type: Journal    
DOI: 10.1590/s0102-86502010000100020     Document Type: Article

References (23)

1. Dantal J, Pohanka E. Malignancies in kidney transplantation: an unmet medical need. Nephrol Dial Transplant. 2007;22(suppl. 1):4-10.
2. Ianhez LE, Paula FJ. Tumores malignos no pós-transplante renal. J Bras Nefrol. 1999;21(4):161-6.
3. Mazzali M. Morbidade e mortalidade em transplante renal no Brasil. Int Braz J Urol. 2004;29(suppl 2):7-14.
4. Silva SL, Silva SF, Cavalcante RO, Mota RS, Carvalho RA, Moraes MO, Campos HH, Moraes ME. Mycophenolate mofetil attenuates Walker's tumor growth when used alone, but the effect is lost when associated with cyclosporine. Transplant Proc. 2004;36(4):1004-6.
5. Alves APNN, Guedes RC, Costa-Lotufo LV, Moraes MEA, Pessoa CO, Ferreira FVA, Moraes MO. Modelo experimental de tumor na cavidade oral de ratos com carcinossarcoma de Walker 256. Acta Cir Bras. 2004;19(4):406-14.
6. Silva LFG, Soares FSD, Anselmo JNN, Fé DMM, Cavalcante JLBG, Moraes MO, Vasconcelos PRL. Modelo de tumor experimental em rim de ratos. Acta Cir Bras. 2002;17(1):62-6.
7. Nicoluzzi JE, Marmamnillo WC, Repka JCD. Transplante simultâneo de pâncreas-rim em portador de Diabetes Mellitus tipo 1 com insuficiência renal crônica. Experiência inicial do Hospital Angelina Caron. Arq Bras Endocrinol Metab. 2003;3:243-7.
8. Barten MJ, Shipkova M, Bartsch P, Dhein S, Streit F, Tarnok A, Armstrong VW, Mohr FW, Oellerich M, Gummert JF. Mycophenolic acid interaction with cyclosporine and tacrolimus in vitro and in vivo: evaluation of additive effects on rat blood lymphocyte function. Ther Drug Monit. 2005;27(2):123-31.
9. Winkler M, Wonigeit K, Undre N, Ringe B, Oldhafer K, Christians U, Pichlmayr R. Comparison of plasma vs whole blood as matrix for FK 506 drug level monitoring. Transplant Proc. 1995;27(1):822-5.
10. Hard GC. Pathology of tumours in laboratory animals. Tumours of the rat. Tumours of the kidney, kidney pelvis and ureter. IARC Sci Publ. 1990;99:301-44.
11. Van Buren D, Payne J, Geevarghese S, MacDonell R, Chapman W, Wright JK, Helderman JH, Richie R, Pinson CW. Impact of sandimmune, neoral, and prograf on rejection incidence and renal function in primary liver transplant recipients. Transplant Proc. 1998;30(5):1830-2.
12. Fujino Y, Kawamura T, Hullett DA, Sollinger HW. Evaluation of cyclosporine, mycophenolate mofetil, and Brequinar sodium combination therapy on hamster-to-rat cardiac xenotransplantation. Transplantation. 1994;57(1):41-6.
13. Greg A, Robert C. Tacrolimus versus cyclosporin for immunosuppression in kidney transplantation: meta-analysis of randomised trials. BMJ. 1999;318:1104-7.
14. Fung JJ. Tacrolimus and transplantation: a decade in review. Transplantation. 2004;77(9 Suppl):S41-3.
15. Christians U, Jacobsen W, Benet LZ, Lampen A. Mechanisms of clinically relevant drug interactions associated with tacrolimus. Clin Pharmacokinet. 2002;41(11):813-51.
16. Gutierrez-Dalmau A, Campistol JM. The role of proliferation signal inhibitors in post-transplant malignancies. Nephrol Dial Transplant. 2007;22(suppl.1):11-6.
17. Kasiske BL, Snyder JJ, Gilbertson DT, Wang C. Cancer after kidney transplantation in the United States. Am J Transplant. 2004;4:905-13.
18. Maluccio M, Sharma V, Lagman M, Vyas S, Yang H, Suthanthiran M. Tacrolimus enhances transforming growth factor-beta1 expression and promotes tumor progression. Source Transplant. 2003;76(3):597-602.
19. Everett V, Sugarbaker MD, Alfred M, Cohen MD, Alfred S, Ketcham MD. Facilitated metastatic distribution of the Walker 256 tumor in sprague-dawley rats with hydrocortisone and/or cyclophosphamide. J Surg Oncol. 1970;2(3):277-89.
20. Taguchi T, Suehiro T, Toru K, Ogami N, Takata H, Hashimoto K. Pleural dissemination of thymoma showing tumor regression after combined corticosteroid and tacrolimus therapy. Eur J Intern Med. 2006;17(8):575-7.
21. Niwa Y, Terashima T, Sumi H. Topical application of the immunosuppressant tacrolimus accelerates carcinogenesis in mouse skin. Br J Dermatol. 2003;149(5):960-7.
22. Shinozuka H, Warty VS, Masuhara M, Murase N, Iwatsuki S. Effect of FK 506 on experimental liver carcinogenesis. Transplant Proc. 1991;23(6):3197-9.
23. Rettori O, Vieira MAN, Gontijo JA. Re-assessment of kidney hydrossaline disfunction in rats bearing Walker-256 tumor. Ren Fail. 2000;22(6):769-84.